ArchiveJune 2020

Live Webinar Tonight 6PM ET! MS and COVID-19: A Webinar Series for Healthcare Providers

Join the National MS Society and the Consortium of MS Centers for a live webinar featuring Gavin Giovannoni, MBBCh, PhD, Chair of Neurology, Blizard Institute Barts and The London School of Medicine and Dentistry and Aaron Miller, MD , Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis. This webinar will focus on disease modifying therapies and clinical decision-making in...

#T4TD – sickness behaviour

This is a first in a new series of ultrashort blog posts called “Thought-4-the-Day” (#T4TD) to make you think about your MS.  Did you know that MS-related fatigue could be caused by sickness behaviour? Sickness behaviour is a coordinated set of adaptive behavioural changes that occur in response to inflammation and/or infection, which includes fatigue or lethargy, depressed mood &...

Do you smoke cannabis?

The findings from this study may interest some of our readers. Cannabis use in MS is licensed for spasticity management and to a lesser extent proven to be helpful with refractory neuropathic pain. Some also use cannabis to manage the psychological downsides of MS. Given it’s increasingly popularity since legalisation, the authors set out to determine whether discontinuing cannabis worsened...

#MSCOVID19: COVAX or Coronavirus Ocrelizumab Vaccination Study

Anti-CD20 therapy not only increases your chances of getting COVID-19 but also increases your chances of developing severe COVID-19 and having to be admitted to hospital for treatment. I have argued that the likely mechanism is to be due to anti-CD20 therapies blunting important cross-reactive anti-coronavirus immune response acquired from other community-acquired coronaviruses. If this is...

Are we over dosing with anti-CD20? Evidence based on rituximab

People with stable MS who were treated with rituximab and then watched remained stable. This should come as nothing new for the general reader but in case you are new to the blog read on Maarouf A, Rico A, Boutiere C, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e825. Published 2020 Jun 25...

What happens with cladribine in the long-term

Abstract Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).Patti F, Visconti A, Capacchione A, Roy S, Trojano M; CLARINET-MS Study Group.Ther Adv Neurol Disord. 2020 Jun 10;13:1756286420922685 Background: The CLARINET-MS study assessed the long-term effectiveness of...

#MSCOVID19 French Registry Reports

The french registry has delivered their first taste of the COVID-19 pot and they support our suggestions that DMT are not creating mega problems if you get infected with SARS-CoV-2. The risk factors are age (co-morbidities increase with age), obesity (co-morbidities increase) and disablity (co-morbidities increase with disability). Interestingly, DMTs were associated with lower risks of severe...

#MSCOVID19: National Seroprevalence Study

We were hoping to do a UK-wide seroprevalence study in UK residents with MS to see how many had seroconverted to become anti-SARS-CoV-2 antibody positive and to see if there are differences in seroconversion rates between people on different DMTs. Unfortunately, our source of funding has fallen through. Based on recent insights we would predict that people on ocrelizumab would have lower titres...

What’s a Blood Spot test

When you are born you had a prick in your heel and you put the blood spot on a card called a Guthrie card. You let the card dry and then you can stick the card in the post. In terms of coronavirus, it will be dead in a couple of days max and it is not going to escape the enveloped to infect the postie A blood spot is about 50-75 microlitres in volume. When the spot is dry the contents are...

Translate

Categories

Recent Posts

Recent Comments

Archives